# MED19

## Overview
MED19 is a gene that encodes the protein mediator complex subunit 19, a component of the Mediator complex, which is integral to the regulation of transcription in eukaryotic cells. The Mediator complex serves as a bridge facilitating communication between transcription factors and RNA polymerase II, thereby influencing gene expression. MED19, specifically, is involved in the repression of neuronal genes in non-neuronal cells and interacts with various transcription factors, including GATA and Hox proteins, through its conserved domains. These interactions are crucial for the regulation of gene expression during development and differentiation (Immarigeon2020Mediator; Boube2014Drosophila). Additionally, MED19 has been implicated in the progression of several cancers, where its altered expression affects key signaling pathways, making it a potential target for therapeutic intervention (Zhang2019Med19; Zhang2022Mediator).

## Structure
The MED19 gene encodes a protein that is a component of the Mediator complex, crucial for transcription regulation. MED19 exists in two isoforms: a canonical form and an alternative splice variant. The canonical isoform is a 244-amino acid protein, while the alternative isoform is a 194-amino acid protein, resulting from the omission of exons 4-5 and featuring four unique amino acids at its C-terminus due to an alternative splice site in exon 3 (Ruoff2023MED19).

The MED19 protein contains several structural domains, including a conserved CORE region and a homeodomain-interacting motif (HIM). These domains are essential for its interaction with GATA transcription factors, specifically binding to the C-zinc finger domain of these proteins (Immarigeon2020Mediator). The CORE domain spans amino acids 126 to 165, and the HIM domain spans amino acids 206 to 220, both of which are necessary for binding (Immarigeon2020Mediator).

MED19 is located in the 'hook' section of the middle module of the Mediator complex, interacting with other subunits such as MED14, MED10, and the N-terminal region of MED1 (Ruoff2023MED19). The specific molecular structure details, such as secondary and tertiary structures, are not provided in the available context.

## Function
MED19 is a subunit of the Mediator complex, which plays a crucial role in transcriptional regulation by facilitating interactions between RNA polymerase II and various transcription factors. In healthy human cells, MED19 is involved in the repression of neuronal gene expression in non-neuronal cells. It forms a trimeric complex with MED12, MED26, the transcription factor REST, and the histone methyltransferase G9a. This complex is essential for recruiting G9a to RE1 silencing elements, leading to the generation of the repressive H3K9me2 mark and subsequent gene repression (Yin2014The; Borggrefe2011Interactions).

MED19's role in stabilizing this complex is critical for REST-directed gene repression, as knockdown of MED19 disrupts the complex, impairing REST-mediated recruitment and leading to the de-repression of target genes (Borggrefe2011Interactions). This suggests that MED19 is important for maintaining the transcriptional repression of neuronal genes in non-neuronal cells, thereby contributing to cell-type-specific gene expression patterns (Yin2014The). MED19 is primarily active in the nucleus, where it influences transcriptional responses that are vital for cellular differentiation and development.

## Clinical Significance
Alterations in the expression of the MED19 gene have been implicated in the progression of several cancers. In breast cancer, MED19 is significantly upregulated and promotes cancer progression by regulating the EGFR/MEK/ERK signaling pathway. Knockdown of MED19 reduces migration, invasion, and epithelial-mesenchymal transition (EMT) in breast cancer cells, suggesting its role in metastasis (Zhang2019Med19). In hepatocellular carcinoma (HCC), MED19 is upregulated and associated with poor prognosis. It promotes HCC development by affecting the AKT/mTOR signaling pathway, influencing cell proliferation, migration, and invasion (Zhang2022Mediator). MED19 is also implicated in osteosarcoma, where its expression correlates with poor prognosis and increased metastasis. Knockdown of MED19 in osteosarcoma cell lines reduces cell migration and proliferation, indicating its oncogenic role (Yu2014Mediator).

In bladder cancer, MED19 is more extensively expressed in cancerous tissues compared to benign tissues. Its knockdown results in cell cycle arrest and reduced cell proliferation, highlighting its role in cancer cell growth (Zhang2012Expression). These findings suggest that MED19 is a potential therapeutic target across various cancer types due to its involvement in critical signaling pathways and cancer progression mechanisms.

## Interactions
MED19, a subunit of the Mediator complex, participates in several critical interactions with transcription factors in Drosophila melanogaster, which may provide insights into its function in humans. MED19 interacts with GATA family transcription factors, such as Pannier (Pnr) and Serpent (Srp), through their conserved C-terminal zinc finger (C-ZF) domains. This interaction is essential for GATA-dependent gene expression, indicating that MED19 acts as a general cofactor for GATA transcription factors (Immarigeon2020Mediator).

MED19 also binds to Hox transcription factors, including Ubx and Dfd, through their homeodomains. This interaction is mediated by a conserved Homeodomain Interacting Motif (HIM) within MED19, which is crucial for the activation of specific target genes by Hox proteins. The HIM domain is necessary for the interaction between MED19 and Hox proteins, and its absence affects the nuclear localization of MED19 (Boube2014Drosophila).

These interactions suggest that MED19 plays a significant role in transcriptional regulation by serving as a bridge between transcription factors and the RNA polymerase II machinery, facilitating the transcription of target genes in developmental processes (Boube2014Drosophila).


## References


[1. (Zhang2019Med19) Xiufen Zhang, Danfeng Gao, Kai Fang, Zijian Guo, and Lihua Li. Med19 is targeted by mir-101–3p/mir-422a and promotes breast cancer progression by regulating the egfr/mek/erk signaling pathway. Cancer Letters, 444:105–115, March 2019. URL: http://dx.doi.org/10.1016/j.canlet.2018.12.008, doi:10.1016/j.canlet.2018.12.008. This article has 22 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.canlet.2018.12.008)

[2. (Zhang2022Mediator) Yuting Zhang, Peifang Qin, Xingfeng Xu, Mao Li, Haitao Huang, Jianguo Yan, and Yali Zhou. Mediator complex subunit 19 promotes the development of hepatocellular carcinoma by regulating the akt/mtor signaling pathway. Frontiers in Oncology, January 2022. URL: http://dx.doi.org/10.3389/fonc.2021.792285, doi:10.3389/fonc.2021.792285. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2021.792285)

[3. (Ruoff2023MED19) Rachel Ruoff, Hannah Weber, Ying Wang, Hongying Huang, Ellen Shapiro, David Fenyö, and Michael J. Garabedian. Med19 encodes two unique protein isoforms that confer prostate cancer growth under low androgen through distinct gene expression programs. Scientific Reports, October 2023. URL: http://dx.doi.org/10.1038/s41598-023-45199-9, doi:10.1038/s41598-023-45199-9. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-023-45199-9)

[4. (Zhang2012Expression) Hu Zhang, Haowen Jiang, Wei Wang, Jian Gong, Limin Zhang, Zhongqing Chen, and Qiang Ding. Expression of med19 in bladder cancer tissues and its role on bladder cancer cell growth. Urologic Oncology: Seminars and Original Investigations, 30(6):920–927, November 2012. URL: http://dx.doi.org/10.1016/j.urolonc.2010.10.003, doi:10.1016/j.urolonc.2010.10.003. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.urolonc.2010.10.003)

5. (Immarigeon2020Mediator) Mediator complex subunit Med19 binds directly GATA DNA-binding zinc finger and functions with Med1 in GATA-driven gene regulationin vivo. This article has 0 citations.

[6. (Borggrefe2011Interactions) Tilman Borggrefe and Xiaojing Yue. Interactions between subunits of the mediator complex with gene-specific transcription factors. Seminars in Cell &amp; Developmental Biology, 22(7):759–768, September 2011. URL: http://dx.doi.org/10.1016/j.semcdb.2011.07.022, doi:10.1016/j.semcdb.2011.07.022. This article has 103 citations.](https://doi.org/10.1016/j.semcdb.2011.07.022)

[7. (Yu2014Mediator) Wenxi Yu, Zhichang Zhang, Daliu Min, Qingcheng Yang, Xuefei Du, Lina Tang, Feng Lin, Yuanjue Sun, Hui Zhao, Shuier Zheng, Aina He, Hongtao Li, Yang Yao, and Zan Shen. Mediator of rna polymerase ii transcription subunit 19 promotes osteosarcoma growth and metastasis and associates with prognosis. European Journal of Cancer, 50(6):1125–1136, April 2014. URL: http://dx.doi.org/10.1016/j.ejca.2014.01.030, doi:10.1016/j.ejca.2014.01.030. This article has 19 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.ejca.2014.01.030)

[8. (Yin2014The) Jing-wen Yin and Gang Wang. The mediator complex: a master coordinator of transcription and cell lineage development. Development, 141(5):977–987, March 2014. URL: http://dx.doi.org/10.1242/dev.098392, doi:10.1242/dev.098392. This article has 161 citations and is from a peer-reviewed journal.](https://doi.org/10.1242/dev.098392)

[9. (Boube2014Drosophila) Muriel Boube, Bruno Hudry, Clément Immarigeon, Yannick Carrier, Sandra Bernat-Fabre, Samir Merabet, Yacine Graba, Henri-Marc Bourbon, and David L. Cribbs. Drosophila melanogaster hox transcription factors access the rna polymerase ii machinery through direct homeodomain binding to a conserved motif of mediator subunit med19. PLoS Genetics, 10(5):e1004303, May 2014. URL: http://dx.doi.org/10.1371/journal.pgen.1004303, doi:10.1371/journal.pgen.1004303. This article has 41 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1371/journal.pgen.1004303)